Remove 2025 Remove Patients Remove Pharmaceutical manufacturing
article thumbnail

Innovative radioligand manufacturing facility inaugurated

European Pharmaceutical Review

The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. The company hopes to produce this number tenfold by the end of 2030.

article thumbnail

WuXi STA breaks ground on new Delaware manufacturing facility

European Pharmaceutical Review

Contract research, development and manufacturing organisation (CRDMO) WuXi STA has broken ground on its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware, US. The WuXi STA Middletown facility is expected to begin operations in 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novo Nordisk plans multi-billion Denmark manufacturing expansion

European Pharmaceutical Review

The construction projects will be finalised from the end of 2025 through to 2029. Novo Nordisk’s Denmark manufacturing facilities Currently, Novo Nordisk’s Kalundborg production facilities manufacture products for treating obesity and diabetes as well as several biopharmaceutical products, employing around 4,400 employees.

article thumbnail

Year in review: EPR’s top stories of 2023

European Pharmaceutical Review

For example, due to prevalence of the disease across the globe, US approval of the biologic lecanemab was particularly anticipated by both the industry and patients. The findings were published in the NEMJ in April 2023 and demonstrated “the best solid tumour CAR-T data reported to date – and by a country mile!

article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

How can we help ensure patients continue to take their medications as prescribed? The reasons why a patient may not take their medication are plentiful, and as a result so are the solutions now available to attempt to solve this issue. billion in 2025. But it is not a simple answer. from 2021 and reach $4.2

article thumbnail

Global Health Equity: Moving From Wish List to To-Do List

Eversana Intouch

Correspondingly, pharmaceutical manufacturers spend exponentially more on marketing healthcare, including more than $6 billion annually on direct-to-consumer advertising. In pharma, we get the chance to do that as we all fight for health equity in 2025 and beyond. If it were easy, wed all be doing it.

article thumbnail

BeiGene enhances biologic capability with new US facility

European Pharmaceutical Review

Addition of our facility at the Princeton West Innovation Campus adds manufacturing and clinical development capabilities…to advance quality medicines faster for patients,” commented John Oyler , Co-Founder, Chairman and CEO of BeiGene. The company highlighted that its oncology pipeline addresses “80 percent of the world’s cancers”.